Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2 studies found for:    15728813 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukaemia Refractory
Intervention: Drug: Rituximab
2 Unknown  A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL
Condition: Chronic Lymphocytic Leukemia
Intervention: Biological: ISF35

Study has passed its completion date and status has not been verified in more than two years.